{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:12:44Z","timestamp":1777673564216,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The p53 protein is a transcription factor for many genes, including genes involved in inhibiting cell proliferation and inducing apoptosis in genotoxically damaged and tumor-transformed cells. In more than 55% of cases of human cancers, loss of the essential function of p53 protein is found. In numerous reports, it has been shown that small molecules (chemical compounds) can restore the suppressor function of the mutant p53 protein in tumor cells. The aim of this study was to evaluate the potential anticancer activity of three newly synthesized olivacine derivatives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was performed using two cell lines\u2014CCRF\/CEM (containing the mutant p53 protein) and A549 (containing a non-mutant, wild-type p53 protein). The cells were incubated with olivacine derivatives for 18\u00a0h and then assays were carried out: measurement of the amount of p53 and p21 proteins, detection of apoptosis, cell cycle analysis, and rhodamine 123 accumulation assay (evaluation of P-glycoprotein inhibition). Multiple-criteria decision analysis was used to compare the anticancer activity of the tested compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Each tested compound caused the reconstitution of suppressor activity of the p53 protein in cells with the mutant protein. In addition, one of the compounds showed significant antitumor activity in both wild-type and mutant cells. For all compounds, a stronger effect on the level of the p53 protein was observed than for the reference compound\u2014ellipticine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The observed effects of the tested new olivacine derivatives (pyridocarbazoles) suggest that they are good candidates for new anticancer drugs.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s43440-019-00004-1","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T14:02:50Z","timestamp":1578492170000},"page":"214-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of new olivacine derivatives on p53 protein level"],"prefix":"10.1007","volume":"72","author":[{"given":"Tomasz","family":"G\u0119barowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benita","family":"Wiatrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"G\u0119bczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Tyli\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"G\u0105siorowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"issue":"3","key":"4_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PAJ Muller","year":"2014","unstructured":"Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304\u201317.","journal-title":"Cancer Cell"},{"issue":"29","key":"4_CR2","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1038\/sj.onc.1206777","volume":"22","author":"YH Peng","year":"2003","unstructured":"Peng YH, Li CG, Chen LH, Sebti S, Chen JD. Rescue of mutant p53 transcription function by ellipticine. Oncogene. 2003;22(29):4478\u201387.","journal-title":"Oncogene"},{"issue":"47","key":"4_CR3","doi-asserted-by":"publisher","first-page":"7486","DOI":"10.1038\/sj.onc.1206949","volume":"22","author":"WS El-Deiry","year":"2003","unstructured":"El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22(47):7486\u201395.","journal-title":"Oncogene"},{"issue":"6","key":"4_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/sj.cdd.4401921","volume":"13","author":"KG Wiman","year":"2006","unstructured":"Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006;13(6):921\u20136.","journal-title":"Cell Death Differ"},{"issue":"3","key":"4_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm0302-282","volume":"8","author":"VJN Bykov","year":"2002","unstructured":"Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8(3):282\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"4_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/00001813-199710000-00001","volume":"8","author":"H Malonne","year":"1997","unstructured":"Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 1997;8(9):811\u201322.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"4_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/mol.53.2.213","volume":"53","author":"S Le Mee","year":"1998","unstructured":"Le Mee S, Pierre A, Markovits J, Atassi G, Jacquemin-Sablon A, Saucier JM. S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol. 1998;53(2):213\u201320.","journal-title":"Mol Pharmacol"},{"issue":"11","key":"4_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1248\/cpb.50.1479","volume":"50","author":"N Haider","year":"2002","unstructured":"Haider N, Sotelo E. 1,5-dimethyl-6H-pyridazino[4,5-b]carbazole, a 3-aza bioisoster of the antitumor alkaloid olivacine. Chem Pharm Bull (Tokyo). 2002;50(11):1479\u201383.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"1","key":"4_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1124\/dmd.32.1.80","volume":"32","author":"L Pichard-Garcia","year":"2004","unstructured":"Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fabre JM, Lucas C, et al. The olivacine derivative S 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture. Drug Metab Dispos. 2004;32(1):80\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4_CR10","first-page":"823","volume":"70","author":"R Jasztold-Howorko","year":"2013","unstructured":"Jasztold-Howorko R, Tyli\u0144ska B, Biadu\u0144 B, G\u0119barowski T, G\u0105siorowski K. New pyridocarbazole derivatives: synthesis and their in vitro anticancer activity. Acta Pol Pharm. 2013;70(5):823\u201332.","journal-title":"Acta Pol Pharm"},{"issue":"3\u20134","key":"4_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/mcda.1514","volume":"21","author":"B Beck","year":"2014","unstructured":"Beck B, Iversen P, Sashegyi A. Combining information for quantitative decision-making in drug development. J Multi-Criteria Decis Anal. 2014;21(3\u20134):139\u201351.","journal-title":"J Multi-Criteria Decis Anal"},{"issue":"9752","key":"4_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558\u201365.","journal-title":"Lancet"},{"key":"4_CR13","doi-asserted-by":"crossref","unstructured":"Sk\u00f3rkowska-Telichowska K, Hasiewicz-Derkacz K, G\u0119barowski T, Kulma A, Moreira H, Kostyn K, et al. Emulsions made of oils from seeds of GM flax protect V79 cells against oxidative stress. Oxid Med Cell Longev 2016.","DOI":"10.1155\/2016\/7510759"},{"issue":"18","key":"4_CR14","doi-asserted-by":"publisher","first-page":"8493","DOI":"10.1073\/pnas.92.18.8493","volume":"92","author":"ML Agarwal","year":"1995","unstructured":"Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2\/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci. 1995;92(18):8493\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"15","key":"4_CR15","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/sj.onc.1204252","volume":"20","author":"WR Taylor","year":"2001","unstructured":"Taylor WR, Stark GR. Regulation of the G2\/M transition by p53. Oncogene. 2001;20(15):1803\u201315.","journal-title":"Oncogene"},{"issue":"1","key":"4_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/108705710200700105","volume":"7","author":"JG Sarver","year":"2002","unstructured":"Sarver JG, Klis WA, Byers JP, Erhardt PW. Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein. J Biomol Screen. 2002;7(1):29\u201334.","journal-title":"J Biomol Screen"},{"issue":"10","key":"4_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"AJ Levine","year":"2009","unstructured":"Levine AJ, Oren M. The first 30\u00a0years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413\u201331.","journal-title":"Cell"},{"issue":"3","key":"4_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ijc.10226","volume":"98","author":"JA Bush","year":"2002","unstructured":"Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer. 2002;98(3):323\u201330.","journal-title":"Int J Cancer"},{"issue":"3","key":"4_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.bbrc.2005.03.190","volume":"331","author":"T Soussi","year":"2005","unstructured":"Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005;331(3):834\u201342.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"4_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1097-2765(03)00050-9","volume":"11","author":"M Mihara","year":"2003","unstructured":"Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11(3):577\u201390.","journal-title":"Mol Cell"},{"issue":"15","key":"4_CR22","doi-asserted-by":"publisher","first-page":"6728","DOI":"10.1128\/MCB.24.15.6728-6741.2004","volume":"24","author":"S Erster","year":"2004","unstructured":"Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol. 2004;24(15):6728\u201341.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"4_CR23","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/cdd.2011.120","volume":"18","author":"V Marcel","year":"2011","unstructured":"Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011;18(12):1815\u201324.","journal-title":"Cell Death Differ"},{"issue":"1","key":"4_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/cgt.2010.63","volume":"18","author":"I Goldstein","year":"2011","unstructured":"Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011;18(1):2\u201311.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"4_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1101\/cshperspect.a000927","volume":"2","author":"MP Khoury","year":"2010","unstructured":"Khoury MP, Bourdon JC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol. 2010;2(3):10.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"4_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.20495","volume":"28","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622\u20139.","journal-title":"Hum Mutat"},{"issue":"17","key":"4_CR27","first-page":"3551","volume":"22","author":"M Hollstein","year":"1994","unstructured":"Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, S\u00f8rlie T, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994;22(17):3551\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"4_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1101\/cshperspect.a001107","volume":"2","author":"M Oren","year":"2010","unstructured":"Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2(2):15.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"4_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2013.07.022","volume":"24","author":"T Cooks","year":"2013","unstructured":"Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-kappa B activation and promotes chronic inflammation and inflammation-associated colorectal cancer (vol 23, pg 634, 2013). Cancer Cell. 2013;24(2):272.","journal-title":"Cancer Cell"},{"issue":"19","key":"4_CR30","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/onc.2010.46","volume":"29","author":"G Schneider","year":"2010","unstructured":"Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, et al. Cross talk between stimulated NF-kappa B and the tumor suppressor p53. Oncogene. 2010;29(19):2795\u2013806.","journal-title":"Oncogene"},{"issue":"6","key":"4_CR31","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/0008-5472.CAN-06-2425","volume":"67","author":"L Weisz","year":"2007","unstructured":"Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, et al. Mutant p53 enhances nuclear factor kappa B activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 2007;67(6):2396\u2013401.","journal-title":"Cancer Res"},{"issue":"1","key":"4_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1368-7646(02)00143-7","volume":"6","author":"NI Valkov","year":"2003","unstructured":"Valkov NI, Sullivan DM. Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat. 2003;6(1):27\u201339.","journal-title":"Drug Resist Updat"},{"issue":"19","key":"4_CR33","first-page":"4285","volume":"57","author":"PM Oconnor","year":"1997","unstructured":"Oconnor PM, Jackman J, Bae I, Myers TG, Fan SJ, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57(19):4285\u2013300.","journal-title":"Cancer Res"},{"issue":"21","key":"4_CR34","doi-asserted-by":"publisher","first-page":"15271","DOI":"10.1074\/jbc.274.21.15271","volume":"274","author":"R Pochampally","year":"1999","unstructured":"Pochampally R, Fodera B, Chen LH, Lu WG, Chen JD. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J Biol Chem. 1999;274(21):15271\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"4_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1006\/bbrc.2000.4056","volume":"279","author":"R Pochampally","year":"2000","unstructured":"Pochampally R, Li CG, Lu WG, Chen LH, Luftig R, Lin J, et al. Temperature-sensitive mutants of p53 homologs. Biochem Biophys Res Commun. 2000;279(3):1001\u201310.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/tlo.09250","volume":"3","author":"Z Wang","year":"2010","unstructured":"Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol. 2010;3(1):1\u201312.","journal-title":"Transl Oncol"},{"issue":"2","key":"4_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ph9020025","volume":"9","author":"CJA Ribeiro","year":"2016","unstructured":"Ribeiro CJA, Rodrigues CMP, Moreira R, Santos MMM. Chemical variations on the p53 reactivation theme. Pharmaceuticals. 2016;9(2):25.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"4_CR38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ccr.2012.03.042","volume":"21","author":"X Yu","year":"2012","unstructured":"Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell. 2012;21(5):614\u201325.","journal-title":"Cancer Cell"},{"issue":"4B","key":"4_CR39","first-page":"3099","volume":"19","author":"E Sugikawa","year":"1999","unstructured":"Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, Ohashi M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res. 1999;19(4B):3099\u2013108.","journal-title":"Anticancer Res"},{"issue":"2","key":"4_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/mol.53.2.241","volume":"53","author":"LM Shi","year":"1998","unstructured":"Shi LM, Myers TG, Fan Y, O\u2019Connor PM, Paull KD, Friend SH, et al. Mining the National Cancer Institute anticancer drug discovery database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol. 1998;53(2):241\u201351.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"4_CR41","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1021\/jo402593w","volume":"79","author":"N Ramkumar","year":"2014","unstructured":"Ramkumar N, Nagarajan R. Total synthesis of ellipticine quinones, olivacine, and calothrixin B. J Org Chem. 2014;79(2):736\u201341.","journal-title":"J Org Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-019-00004-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T10:28:46Z","timestamp":1665397726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-019-00004-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s43440-019-00004-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"11 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}